Opinion

Video

Toxicity Considerations and Treatment Decisions in CRC

Author(s):

John Strickler, MD,Arvind N. Dasari, MD, MS

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Stephanie Graff, MD, and Chandler Park, FACP
2 experts in this video
2 experts in this video
Elias Jabbour, MD
Related Content
FDA
December 20th 2024

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

ASH Meeting | Image credit: © Nittaya – stock.adobe.com
December 9th 2024

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

Elias Jabbour, MD, a professor in the Department of Leukemia, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center in Houston
December 6th 2024

ALL Treatment Paradigm Displays Significant Gains as NCCN Guidelines Evolve

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024